Andrew Greene

Andrew Greene was senior consultant at Merlin Biosciences until December 2003. He sits on the board of the Royal Society's Working party on peer review.

Greene joined Merlin from Merrill Lynch International, where he was Director of Healthcare Investment Banking. He ran the Healthcare Investment Banking team at HSBC Investment Bank. His team advised biotechnology companies in Europe on fundraising and mergers and acquisitions. He also worked for the international management consulting firms Booz, Allen & Hamilton, Inc. and Cap Gemini Sogeti, where he advised major private equity groups on healthcare acquisitions and leveraged buyouts, and also advised hospital, drug, medical device, and insurance companies on corporate strategy. Mr Greene worked in Corporate Treasury for Lifemark Corporation and was involved in the sale of Lifemark to American Medical International (now Tenet Healthcare). His first medical work was on a $10 million NIH grant at Harvard Medical School / Massachusetts General Hospital. He has an MBA / Masters of Accounting degree from Rice University and a BA from Cornell University. [1]

References

• Sachs-Bloomberg Annual Global Biotech Forum, Andrew Greene (speaker biography), accessed January 2004
• Paul Durman, Merlin chief quits at end of a tough year, The Sunday Times, December 28, 2003